Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 1999, p. 1511-1515, Vol. 43, No. 6
EA 1223, Faculté de Médecine & Pharmacie, Universite de Poitiers, Poitiers, France
Received 11 September 1998/Returned for modification 30 January
1999/Accepted 7 March 1999
The in vivo convulsant activities in rats of five representative
fluoroquinolones (FQs), norfloxacin, enoxacin, sparfloxacin, fleroxacin, and pefloxacin, were compared. The experimental approach allowed distinction between the drugs' ability to reach the
pharmacological receptors at the level of the central nervous system
(pharmacokinetic contribution) and their ability to interact with these
receptors (pharmacodynamic contribution). The presence of a methyl
group on the piperazine moiety decreased the pharmacodynamic
contribution to the convulsant activity by severalfold, and the ratios
of concentrations of the FQs in cerebrospinal fluid (CSF) to
concentrations of unbound FQs in plasma varied from about 5 to 75% as
a function of lipophilicity. Interestingly, FQs with the highest
intrinsic convulsant activities had the lowest levels of diffusion in
CSF and vice versa. This in vivo approach provides information
complementary to that of in vitro experiments and should be recommended
for early preclinical assessment of a new FQ's epileptogenic risk.
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Pharmacokinetic-Pharmacodynamic Contributions to
the Convulsant Activity of Fluoroquinolones in Rats
*
Corresponding author. Mailing address: Laboratoire de
Pharmacie Galénique et Biopharmacie, Faculté de
Médecine & Pharmacie, 34 rue du Jardin des Plantes, 86005 Poitiers Cédex, France. Phone: (33-5) 49.45.43.79. Fax: (33-5)
49.45.43.78. E-mail:
William.Couet{at}campus.univ-poitiers.fr.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»